In this article by Zena Olijnyk for Lexpert, readers see how U.S. tariff threats and economic uncertainty are putting Canadian health and life sciences dealmaking on hold. Buyers and sellers are holding off on mergers and acquisitions until trade and pricing risks are clearer. Industry experts warn that delays can drive up transaction costs, slow innovation, and deter global investment from coming to Canada. Prolonged uncertainty could leave promising research underfunded, limit growth for emerging companies, and ultimately delay patient access to new treatments.